# PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

> **NCT03423199** · PHASE3 · UNKNOWN · sponsor: **National Cancer Center, Japan** · enrollment: 180 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Placebo
- **DRUG:** Tamoxifen
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT03423199
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-09
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423199, "PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03423199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*